Cytoplasmic Her2/neu immunohistochemical staining in breast cancer; From a molecular point of view
The most widely used guideline for the breast cancer biomarker assessment and reporting (the 2013 ASCO/CAP guideline) does not state the unusual occurrence of cytoplasmic Her2/neu staining (1, 2). We recently encountered a T2N1Mx ductal adeno-carcinoma which consisted of two dissimilar tumor cell po...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
Iranian Society of Pathology,
2019-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|